Find a world of support about living as a young woman with primary breast cancer.
Younger Women Together
Although it might feel like you’re the only younger woman with breast cancer, you’re not alone. If you’re aged 20-45 and have a diagnosis of primary breast cancer our Younger Women Together events give you the opportunity to meet with and share your experiences with other younger women – whether you’re currently going through treatment or trying to find your ‘new normal’ after treatment.
These new one-day events take place across the UK and you’ll be able to get expert information and explore important topics such as intimacy, fertility and coping with change and uncertainty. Our events include small group discussions, with support from expert facilitators, Breast Cancer Now’s Younger Women’s Clinical Nurse Specialist and trained volunteers who have all experienced breast cancer as younger women.
To find out more and register for an event in your area, please select the dates below:
- Belfast - Saturday 11 June 9.30am - 4.30pm
- Bristol - Saturday 2 July 9.30am - 4.30pm
- Newcastle - Saturday 16 July 9.30am - 4.30pm
Younger Women Together Online
If you’re under 45 and have had a primary breast cancer diagnosis within the last three years, our new Younger Women Together Online service is just for you. In a confidential online space, you’ll meet other women your age who understand what you’re going through and be able to access expert information on treatment, fertility, exercise and more.
Our upcoming series start on the below dates. Please select a date to find out more and register:
Younger Women Together - Webinars
Do you want to learn more about healthy eating, exercise and returning to work? Come along to our live talks by expert speakers via Zoom webinar – you can attend all of them or select the ones which interest you.
There will be an opportunity to send questions before or during the talk.
Younger Women Together Online has been created whilst Breast Cancer Now’s face-to-face services are suspended due to the Covid-19 crisis. We’re always with you, even when we can’t get to you.
Our speakers events take place on the below dates:
Thursday 19th May at 2pm Triple Negative Breast Cancer and Younger Women with Prof Peter Schmid
Professor Schmid is internationally recognized for his research and education leadership in breast cancer. He is the clinical director of the Breast Cancer Centre and an honorary consultant medical oncologist at St. Bartholomew’s Hospital. He was appointed in 2013 as Chair in Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University, London. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute, overseeing the conduct of early phase trials at St. Bartholomew’s Hospital and BCI, with a particular interest in Immunotherapy, innovative trial designs, and circulating biomarkers. He leads the academic breast cancer programme at St. Bartholomew’s Hospital and BCI.
Prof Schmid graduated from the Technical University of Munich medical school in 1997, gaining a MD in Clinical Chemistry in 1998 from the University of Munich and a Clinical Research PhD in 2005 from Charité University in Berlin. He trained at the University Hospital Charité in Berlin in internal medicine, haematology, and oncology, before he became a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London in 2005. Professor Schmid was appointed as Foundation Chair in Cancer Medicine at the University of Sussex in 2010 before taking on his current role at BCI in 2013.
Professor Schmid’s primary research interest is in clinical research in breast cancer with the goal of improving the treatment of women with breast cancer by defining more effective and less toxic approaches. Specific research areas include cancer immune therapy, triple-negative breast cancer, endocrine resistance, and innovative biomarker-driven trial concepts. Professor Schmid runs an international collaborative clinical and translational research programme.
Professor Schmid is the principal investigator of several pivotal breast cancer studies, including the Impassion130 trial that evaluated atezolizumab for advanced triple-negative breast cancer and led to the regulatory approval of the first immunotherapy strategy for patients with breast cancer, establishing a new standard of care of this disease. Professor Schmid is also the lead investigator of the KEYNOTE-522 trial which evaluated the immune-checkpoint inhibitor Pembrolizumab in combination with neoadjuvant chemotherapy for early triple-negative breast cancer and demonstrated a significant increase in pathological response rates. His work has been published in many journals including the New England Journal of Medicine, Lancet, Lancet Oncology, JAMA Oncology, Nature Communications and the Journal of Clinical Oncology.
Prof Schmid is a member of several national and international cancer organisations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Peter Schmid is a member of the European Society for Medical Oncology (ESMO) breast cancer faculty.
Thursday 26th May at 7pm Coping with Change and Uncertainty with Catarina Baptista
Catarina Baptista, registered Practitioner Clinical Psychologist and Chartered Psychologist (Cpsychol) and Senior specialist Clinical and Health Psychologist (Portuguese registration). For the past 16 years I've been working as a clinical psychologist in Portugal, Central America and the UK and dedicated part of my time to supervision, teaching and research. This experience has enabled me to work with a wide range of people and mental health presentations. My latest professional pathway has been in health psychology and psych oncology working for Maggies Centre. A substantial part of my work and research is in women cancer care, particularly young women.
Wednesday 15th June at 7pm Breast Reconstruction with Mr James Harvey
Mr Harvey is dual trained in both Plastic Surgery and Cancer Surgery of the Breast and has been a Consultant Oncoplastic Breast Surgeon at the Nightingale and Prevent Breast Cancer Prevention Centre, at Manchester University NHS Foundation Trust since 2012. The Nightingale Centre is nationally recognised as a centre of excellence for breast cancer treatment and is the largest unit in the UK. Mr Harvey also consults privately, exclusively at the BMI Alexandra hospital in Cheadle, Manchester.
Mr Harvey's specialist area is exclusively breast disease and breast related problems, i.e., breast cancer surgery, breast reconstruction, aesthetic breast surgery and lipomodelling / fat transfer. Mr Harvey performs only breast cosmetic surgery, reconstructive and revisional surgery. His reputation for excellence has made him an International speaker on the topics. Mr Harvey is an invited speaker at International Breast Reconstructive meetings including the Oncoplastic and Reconstructive Breast Cancer (ORBS) conference, Milano Breast Conference, Amsterdam Breast Conference and is a trainer for Allergan.
Mr Harvey is National lead for multiple trials in Manchester and in the UK, mainly introducing innovation to breast surgery and ensuring high quality outcomes for patients, particularly those having cancer and reconstructive surgery. Mr Harvey’s team is experienced in coordinating care for overseas patients and is happy to consult for patients who live outside the UK, who would like to travel to Manchester for an opinion, or for their treatment.
Mr Harvey is an active trainer, participating in the teaching of trainee breast and plastic surgeons at local, national land international levels. Mr Harvey has consulted for Roche, Allergan, Lifecell, Johnson and Johnson, Endomagnetics and Hologic.